Small-molecule Malaria treatment and prevention strategy
Malaria has created a global health crisis that affects 500 million people worldwide each year. The parasite that causes malaria, Plasmodium falciparum, is adaptive and readily develops drug resistance. Therefore, there is a pressing need to develop new treatments as existing treatments become increasingly obsolete. This technology is a library of small-molecules that inhibit a target protein, Equilibrative Nucleoside Transporter 1 (PfENT1), preventing the parasite's proliferation. These compounds provide a strategy for developing new malaria treatments and preventative therapeutics.
PfENT1 is a drug target for the malaria parasite, P. falciparumPatent Information:Patent Pending (WO/2014/210319)Tech Ventures Reference: IR CU13311
Potential drug treatment for malaria and cerebral malariaPotential prophylaxis for malariaPotential drug target for other parasitic diseasesBasic research on PfENT1 inhibition
None
美国
